Please use this identifier to cite or link to this item: https://doi.org/10.1038/s41392-018-0010-0
Title: Pan-CDK inhibition augments cisplatin lethality in nasopharyngeal carcinoma cell lines and xenograft models
Authors: Syn N.L.
Lim P.L.
Kong L.R.
Wang L. 
Wong A.L.-A. 
Lim C.M. 
Loh T.K.S. 
Siemeister G.
Goh B.C. 
Hsieh W.-S. 
Issue Date: 2018
Publisher: Springer Nature
Citation: Syn N.L., Lim P.L., Kong L.R., Wang L., Wong A.L.-A., Lim C.M., Loh T.K.S., Siemeister G., Goh B.C., Hsieh W.-S. (2018). Pan-CDK inhibition augments cisplatin lethality in nasopharyngeal carcinoma cell lines and xenograft models. Signal Transduction and Targeted Therapy 3 (1) : 9. ScholarBank@NUS Repository. https://doi.org/10.1038/s41392-018-0010-0
Abstract: In addition to their canonical roles in regulating cell cycle transition and transcription, cyclin-dependent kinases (CDKs) have been shown to coordinate DNA damage response pathways, suggesting a rational pairing of CDK inhibitors with genotoxic chemotherapeutic agents in the treatment of human malignancies. Here, we report that roniciclib (BAY1000394), a potent pan-CDK inhibitor, displays promising anti-neoplastic activity as a single agent and potentiates cisplatin lethality in preclinical nasopharyngeal carcinoma (NPC) models. Proliferation of the NPC cell lines HONE-1, CNE-2, C666-1, and HK-1 was effectively curbed by roniciclib treatment, with IC50 values between 11 and 38 nmol/L. These anticancer effects were mediated by pleiotropic mechanisms consistent with successful blockade of cell cycle CDKs 1, 2, 3, and 4 and transcriptional CDKs 7 and 9, ultimately resulting in arrest at G1/S and G2/M, downregulation of the transcriptional apparatus, and repression of anti-apoptotic proteins. Considerably enhanced tumor cell apoptosis was achieved following combined treatment with 10 nmol/L roniciclib and 2.0 ?mol/L cisplatin; this combination therapy achieved a response over 250% greater than either drug alone. Although roniciclib chemosensitized NPC cells to cisplatin, it did not sensitize untransformed (NP69) cells. The administration of 0.5 mg/kg roniciclib to BALB/c xenograft mice was well tolerated and effectively restrained tumor growth comparable to treatment with 6 mg/kg cisplatin, whereas combining these two agents produced far greater tumor suppression than either of the monotherapies. In summary, these data demonstrate that roniciclib has strong anti-NPC activity and synergizes with cisplatin chemotherapy at clinically relevant doses, thus justifying further evaluation of this combinatorial approach in clinical settings. © 2018, The Author(s).
Source Title: Signal Transduction and Targeted Therapy
URI: http://scholarbank.nus.edu.sg/handle/10635/151596
ISSN: 20959907
DOI: 10.1038/s41392-018-0010-0
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
s41392-018-0010-0.pdf3.89 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

3
checked on Oct 20, 2019

Page view(s)

49
checked on Oct 17, 2019

Download(s)

3
checked on Oct 17, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.